According to a study published in Nature Neuroscience, Alzheimer’s disease neurodegeneration may be driven primarily by an external immune response rather than damage originating strictly inside the brain. Washington University in St. Louis neurologist David Holtzman and his research team found that CD8+ T cells are directed into the brain via conventional type 1 dendritic cells (cDC1s), indicating that therapies targeting the body’s lymphatic processes could treat neurological disorders without needing to cross the blood-brain barrier.
How Immune Cells Outside the Brain Drive Neurodegeneration
Medical science has traditionally viewed Alzheimer’s disease strictly as an internal brain disorder characterized by protein accumulation. However, according to findings published in Nature Neuroscience, an immune response originating outside the central nervous system attacks the brain to cause neurodegeneration. In previous work, Holtzman’s team discovered that T cells appeared in high abundance within the brains of mice exhibiting elevated levels of tau protein. When researchers eliminated or blocked those T cells, neuronal damage dropped significantly.
“Until not that long ago, most people, including myself, did not think that the immune response was even involved in neurodegenerative diseases that are due to protein accumulation in the brain,” Holtzman said according to the study. “We’ve shown they’re important, and that they are a potential target for future therapy.”
The Role of cDC1 Sentinels and CD8+ T Cells
To uncover why these immune cells activate and infiltrate neural tissue, the researchers conducted experiments with mice engineered to develop tau pathology. The team discovered that CD8+ T cells—which normally destroy cancerous or abnormal cells—enter the brain due to interactions with conventional type 1 dendritic cells, or cDC1s. These cDC1s act as immune system sentinels that identify molecular signatures and signal detection to CD8+ T cells through a process called cross-presentation.
When researchers experimentally eliminated cDC1 sentinel cells or disrupted their cross-presentation ability, signs of neurodegeneration and neuroinflammation dropped substantially compared to control mice with unimpaired cDC1 functions. Furthermore, silencing these sentinel cells reduced the total number of CD8+ T cells infiltrating the brain. Interestingly, altering the cDC1 cells did not significantly change the amount of tau protein in the animals’ brains. This suggests that while neurodegeneration relates to tau accumulation, the external immune response acts as a primary driver of actual brain damage.
Activation in Deep Cervical Lymph Nodes
Because cDC1s were rarely detected inside the brain even during severe degeneration, researchers hypothesized that cell signaling must occur elsewhere in the body. Separate experiments confirmed that CD8+ T cells activate within deep cervical lymph nodes located in the neck. Recent evidence shows these lymph nodes play a critical role in neurological diseases when their function as a drainage system for brain waste products falters.
“We propose that tauopathy induces neuronal injury, resulting in the release of antigens that are captured by cDC1s to prime CD8+ T cells,” the researchers wrote in their paper. As tau accumulates, released antigens travel downstream to the deep cervical lymph nodes. There, they trigger cDC1s to alert CD8+ T cells, which travel back upstream to the brain and cause neuroinflammation.
Pro Tip: Researchers emphasize that future treatments might bypass the central nervous system entirely, utilizing existing, approved therapies that manipulate T cells outside the blood-brain barrier.
New Treatment Pathways and Overcoming the Blood-Brain Barrier
Developing medications for neurological diseases historically requires engineering drugs to cross the protective blood-brain barrier. However, the discovery that immune priming occurs outside the brain changes this paradigm. “There are lots of ways to manipulate T cells that have been studied extensively and that are approved treatments for other diseases, but many haven’t yet been explored for neurodegenerative diseases,” Holtzman noted.
Did You Know? Deep cervical lymph nodes in the neck serve as drainage pathways for waste products coming from the brain, potentially acting as the primary site where immune cells first encounter neurodegenerative antigens.
Frequently Asked Questions
Does Alzheimer’s disease start outside the brain?
According to research published in Nature Neuroscience, while tau accumulation happens inside the brain, the resulting neurodegeneration may be heavily driven by an immune response originating outside the brain.
What are cDC1 cells?
Conventional type 1 dendritic cells (cDC1s) act as immune system sentinels that identify targets and signal CD8+ T cells to execute immune functions.
Do treatments need to cross the blood-brain barrier?
Not necessarily. Because immune activation appears to happen in the lymph nodes of the neck, future therapies might manipulate T cells outside the central nervous system.
Explore more medical research breakthroughs and subscribe to our newsletter for the latest updates on neurological science.
Worth a look